The PMPRB is holding public consultations on its proposed new pricing Guidelines
OTTAWA, ON, June 19, 2020 /CNW/ - The Patented Medicine Prices Review Board (PMPRB) launched a 30-day public consultation today on its updated draft pricing Guidelines. The updated draft Guidelines have been significantly changed in response to stakeholder feedback on an earlier draft that was released in November 2019 for an 85-day consultation period.
The Guidelines explain the steps taken by staff at the PMPRB in assessing whether a patented medicine appears to be priced excessively in Canada. It also explains what information patent-holding pharmaceutical companies must provide to the PMPRB to enable it to make that assessment.
This consultation follows Health Canada's amendments to the Patented Medicines Regulations, which strengthen and modernize Canada's pricing framework for patented medicines so that the PMPRB can better protect Canadian consumers from excessive prices in an era marked by increasingly high cost drugs.
The deadline for providing written submissions is July 20, 2020. The PMPRB will be hosting a series of webinars to discuss the draft Guidelines with stakeholders. Details are available on the PMPRB's website.
Quick Facts
- The Patented Medicines Regulations will come into force on January 1, 2021.
- Major changes to the PMPRB's Guidelines are necessary to implement the regulatory amendments.
- The PMPRB ensures that prices charged by pharmaceutical companies for patented drugs sold in Canada are not excessive.
- The PMPRB also reports on pharmaceutical trends and R&D spending by pharmaceutical patentees.
Associated Links
Follow us on Twitter: @PMPRB_CEPMB
SOURCE Patented Medicine Prices Review Board
PMPRB Media Relations, [email protected], TTY (telecommunications device for the hearing impaired) - 613-288-9654
Related Links
https://www.canada.ca/en/patented-medicine-prices-review.html
Share this article